Brief: Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences
27/02/2025 09:52
Feb 27 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCES REGARDING PROJECT IL-29 SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCES CO, SCIWIND BIOSCIENCES ESTABLISHED EXCLUSIVITY ON LICENSING AND COOPERATION IN 19 COUNTRIES FOR HUMAN INTERLEUKIN-29 PROJECT Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit